Serial ctDNA Monitoring to Advance Oncology Drug Development: Clinical Value, Reimbursement Barriers in Japan, & Lessons from Takeda’s mCRC Study

• The importance of longitudinal ctDNA monitoring (pre-/on-treatment)
• The challenges of routine implementation under Japan’s current reimbursement framework
• Insights from our mCRC clinical study on how serial ctDNA dynamics may inform patient stratification and CDx utility

Speakers:

Kazunori Yamanaka

Lead, Medical Bioinformatics & Translational Research

Takeda Pharmaceutical